Cardosten - instructions for use, dose, side effects, contraindications

Similar drugsTo uncover

Dosage form: & nbsplozenges

Composition:

Active components:

Antibodies to the C-terminal fragment of the AT1 receptor of angiotensin II affinity purified - 0.003 g *

Excipients: lactose monohydrate (lactose) 0.267 g, microcrystalline cellulose 0.03 g, magnesium stearate 0.003 g

* are applied to lactose in the form of a water-alcohol mixture with a content of not more than 10^-15 ng / g of the active form of the active ingredient.

Description:Tablets are flat-cylindrical, with a risk and chamfer, from white to almost white. On the flat side, the inscription MATERIA MEDICA is marked with a risk, on the other flat side is inscribed CARDOSTEN.

Pharmacotherapeutic group:Angiotensin II receptor modulator

ATX: & nbsp

Angiotensin II antagonists

Pharmacodynamics:

The drug modulates the functional activity of AT₁ subtype of angiotensin II receptors in various tissues.

In conditions of chronic heart failure (CHF), the drug reduces arterial vasoconstriction, peripheral vascular resistance, pre - and postnagruzku on the heart. Modifies the effect of angiotensin II on the structure and function of resistive vessels, remodeling processes in the cardiovascular system; positively affects the morphofunctional parameters of the heart, including helps reduce myocardial hypertrophy, reduce the volume of dilated heart chambers, normalize myocardial oxygenation. By increasing the stroke volume increases the minute volume of blood flow, without changing the heart rate.

The drug increases exercise tolerance and improves the functional class of CHF. Taking a drug lasting two or more months is accompanied by an improvement in hemodynamic parameters; leads to the normalization of the daily rhythm of blood pressure (BP) (does not affect blood pressure at its normal level, reduces blood pressure at initially elevated values, reduces its fluctuations during the day).

Does not adversely affect the water-salt balance.

Pharmacokinetics:The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-small doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of Cardosten.

Indications:As part of a comprehensive therapy for chronic heart failure to reduce shortness of breath, weakness, severity of peripheral edema; increase tolerance to physical activity.

Contraindications:

Increased individual sensitivity to the components of the drug.

It is not recommended for use in children and adolescents under the age of 18 (due to lack of clinical experience).

Pregnancy and lactation:The safety of the use of Cardosten in pregnant women and during lactation has not been studied. If necessary, taking the drug should take into account the risk / benefit ratio.

Dosing and Administration:

Inside. The drug is taken for a long time. The first 2-3 months of treatment with Cardosten is carried out without canceling the previously prescribed complex therapy for chronic heart failure, the amount of which can be changed in the future by the attending physician.

At one time - 1 tablet (keep in your mouth until completely dissolved - not during meals). If necessary, it is possible to use 2 tablets at the reception.

The first 2-3 months the drug is taken 3 times a day. With the improvement of the state, two doses of the drug are sufficient per day - before bedtime and in the morning.

Side effects:Possible reactions of increased individual sensitivity to the components of the drug.

Overdose:

There have been no cases of overdose to date.

In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.

Interaction:

Cases of incompatibility with other drugs have not been identified to date.

The use of beta-blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, calcium antagonists, nitrates, diuretics, cardiac glycosides increases the effect of the latter when used in patients with CHF.

Special instructions:

The composition of the drug includes lactose, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase deficiency.

Effect on the ability to drive transp. cf. and fur:Cardosten does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Form release / dosage:Lozenges.

Packaging:For 20 tablets in a planar cell pack. For 1, 2 or 5 contour mesh packages, together with instructions for medical use, put in a pack of cardboard.

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

During the period of application of the drug, store the contour mesh package in a cardboard bundle,provided by the manufacturer.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LS-001322

Date of registration:21.06.2010 / 18.05.2012

Expiration Date:Unlimited

The owner of the registration certificate:NPF Materia Medica Holding, OOO NPF Materia Medica Holding, OOO Russia

Manufacturer: & nbsp

NPF Materia Medica Holding, OOO Russia

Representation: & nbspMAGNOLIA SMPP, LLCMAGNOLIA SMPP, LLC

Information update date: & nbsp12.12.2017

Illustrated instructions

Instructions

Kardosten (Kardosten)